McKesson Plans to Acquire Rx Savings Solutions

On Monday, September 19, McKesson announced that it had signed an agreement with Rx Savings Solutions. This agreement focuses on the company’s plans to acquire Rx Savings Solutions to advance the goals of both organizations, including improved access, affordability, and adherence solutions.

Rx Savings Solutions (RxSS) is focused on price transparency and works to provide patients with information on medications, their affordability, and more. Currently, the company reaches approximately 17 million patients.

According to the press release, RxSS uses machine learning algorithms to analyze different therapeutic options and their cost efficacy. The company also works with health plans and employers directly.

"Rx Savings Solutions' offerings for employers and patients will strengthen McKesson's ability to help solve the most common medication challenges related to access, affordability, and adherence," said Brian Tyler, chief executive officer of McKesson, in the press release. "We expect the acquisition of Rx Savings Solutions to accelerate McKesson's growth priority in biopharma services by extending our ecosystem of differentiated medication access solutions to patients. Together with Rx Savings Solutions, McKesson will amplify our efforts to advance health outcomes for all."

McKesson will pay approximately $600 million upfront to acquire the company, but the overall value of the transaction may be up to $875 million. Based on financial performance through 2025, RxSS may make an additional $275 million.

Once the company is fully acquired, RxSS will be hosted under McKesson’s Prescription Technology Solutions. This sector of the company works to improve access, affordability, and adherence for patients.

As the organization announced, “after initial integration, McKesson expects to use the combined medication access, affordability, and adherence services as a foundation to build new outcomes management programs for biopharma and payers, differentiated by their reach and efficacy at three touchpoints: provider office, pharmacy counter, and direct patient tools.”

As this agreement closes and the company is acquired, industry members and providers will monitor the impacts of this relationship on prescription costs, patient accessibility, and multiple other aspects of patient life.